Contents

Current Molecular Pharmacology, Volume 5 - Number 2

EDITORIAL [Hot Topic-I: Molecular and Pharmacological Aspects of Existing and Experimental Bone Anabolic Therapies (Guest Editor: Naibedya Chattopadhyay)]

, 5(2): 125 - 126

Naibedya Chattopadhyay


DOI: 10.2174/1874467211205020125




Anabolic Effects of Intermittent PTH on Osteoblasts

, 5(2): 127 - 134

Edward M. Greenfield


DOI: 10.2174/1874467211205020127




Insulin Like Growth Factor-I: A Critical Mediator of the Skeletal Response to Parathyroid Hormone

, 5(2): 135 - 142

Daniel D. Bikle and Yongmei Wang


DOI: 10.2174/1874467211205020135




Insulin-Like Growth Factor-I Molecular Pathways in Osteoblasts: Potential Targets for Pharmacological Manipulation

, 5(2): 143 - 152

Kristen E. Govoni


DOI: 10.2174/1874467211205020143




The Role of BMPs in Bone Anabolism and their Potential Targets SOST and DKK1

, 5(2): 153 - 163

Nobuhiro Kamiya


DOI: 10.2174/1874467211205020153




Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent

, 5(2): 164 - 173

Ulf Krause and Carl A. Gregory


DOI: 10.2174/1874467211205020164




Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists

, 5(2): 174 - 181

Joseph Pagkalos, Andreas Leonidou, Mohammed As-Sultany, Manolis Heliotis, Athanasios Mantalaris and Eleftherios Tsiridis


DOI: 10.2174/1874467211205020174




Antagonizing the Calcium-Sensing Receptor: Towards New Bone Anabolics?

, 5(2): 182 - 188

Daniela Riccardi


DOI: 10.2174/1874467211205020182




Potential Anti-Catabolic and Anabolic Properties of Strontium Ranelate

, 5(2): 189 - 194

Romuald Mentaverri, Michel Brazier, Said Kamel and Patrice Fardellone


DOI: 10.2174/1874467211205020189




Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis

, 5(2): 195 - 204

Sutada Lotinun, R. Scott Pearsall, William C. Horne and Roland Baron


DOI: 10.2174/1874467211205020195




Naturally Plant-Derived Compounds: Role in Bone Anabolism

, 5(2): 205 - 218

Marie-Noelle Horcajada and Elizabeth Offord


DOI: 10.2174/1874467211205020205




EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]

, 5(2): 219 - 223

Pitchai Balakumar and Gowraganahalli Jagadeesh


DOI: 10.2174/1874467211205020219




The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress

, 5(2): 224 - 240

M. C. Sugden, M. P. Warlow and M. J. Holness


DOI: 10.2174/1874467211205020224




Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)

, 5(2): 241 - 247

Tom Hsun-Wei Huang and Basil D. Roufogalis


DOI: 10.2174/1874467211205020241




Effects of PPARγ Agonists against Vascular and Renal Dysfunction

, 5(2): 248 - 254

Akira Sugawara, Akira Uruno, Ken Matsuda, Takako Saito-Ito, Tadao Funato, Akiko Saito-Hakoda, Masataka Kudo and Sadayoshi Ito


DOI: 10.2174/1874467211205020248




Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?

, 5(2): 255 - 263

Satyam Sarma


DOI: 10.2174/1874467211205020255




Assessment of Cardiac Safety for PPARγ Agonists in Rodent Models of Heart Failure: A Translational Medicine Perspective

, 5(2): 264 - 271

Xinkang Wang


DOI: 10.2174/1874467211205020264




Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk

, 5(2): 272 - 281

Giuseppe Derosa and Pamela Maffioli


DOI: 10.2174/1874467211205020272




Effects of PPARγ Ligands on Vascular Tone

, 5(2): 282 - 291

Salvatore Salomone and Filippo Drago


DOI: 10.2174/1874467211205020282




PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders

, 5(2): 292 - 300

Shizuko Nagao and Tamio Yamaguchi


DOI: 10.2174/1874467211205020292




The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development

, 5(2): 301 - 316

Toshiyuki Mikami, Mikio Aoki and Toru Kimura


DOI: 10.2174/1874467211205020301




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science